

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT06667414

Status RECRUITING
Sponsor Hoffmann-La Roche
Enrollment 600 participants

Key Eligibility Criteria

Inclusion (5)

- Have signed the Informed Consent Form (ICF)
- Aged 25 to 60 years, inclusive, at the time of signing the ICF
- Confirmation of Huntington Disease (HD) gene expansion mutation carrier status
- Confirmation of Total Functional Capacity (TFC) ≥ 9 and Total Motor Score (TMS) ≥ 6 within 12 months prior to signing the ICF
- Ability to tolerate blood draws

Exclusion (1)

- None

Locations (45 total)

Uab Medicine, Birmingham, Alabama, United States
Barrow Neurological Institute, Phoenix, Arizona, United States
University of California San Diego, La Jolla, California, United States
... and 42 more locations

<https://clinicaltrials.gov/study/NCT06667414>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.